van Hees P A, Bakker J H, van Tongeren J H
Gut. 1980 Jul;21(7):632-5. doi: 10.1136/gut.21.7.632.
Suppositories of sulphapyridine, 5-aminosalicylic acid, and placebo were used in 45 patients with idiopathic proctitis to determine the active part of sulphasalazine. Each patient used one of the suppositories twice daily for four weeks in a double-blind controlled trial. Complete clinical remission with normal rectal mucosa on sigmoidoscopy occurred in 60% of patients given 5-aminosalicylic acid, but in only 13% and 27% of those given sulphapyridine and placebo respectively. Twelve patients were included twice. In eight of these patients 5-aminosalicylic acid was given one time and sulphapyridine (two patients) or placebo (six patients) another time. Clinical remission occurred in each patient with 5-aminosalicylic acid, but in only one patient during other therapy. The results suggest that 5-aminosalicylic acid is the active therapeutic moiety of sulphasalazine.
使用磺胺吡啶栓、5-氨基水杨酸栓和安慰剂对45例特发性直肠炎患者进行试验,以确定柳氮磺胺吡啶的活性成分。在一项双盲对照试验中,每位患者每天使用其中一种栓剂两次,持续四周。乙状结肠镜检查显示直肠黏膜正常且达到完全临床缓解的情况,在使用5-氨基水杨酸栓的患者中占60%,而在使用磺胺吡啶栓和安慰剂的患者中分别仅占13%和27%。有12名患者参与了两次试验。在这些患者中,8名患者一次使用5-氨基水杨酸栓,另一次使用磺胺吡啶栓(2名患者)或安慰剂(6名患者)。使用5-氨基水杨酸栓时,每位患者均出现临床缓解,但在接受其他治疗时只有1名患者出现临床缓解。结果表明,5-氨基水杨酸是柳氮磺胺吡啶的活性治疗部分。